REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS
Clinical trials for REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS trials appear
Sign up with your email to follow new studies for REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for aggressive lymphoma: drug combo aims to unmask cancer cells
Disease control OngoingThis study tests a combination of two drugs (TTI-622 and pembrolizumab) in about 10 adults with diffuse large B-cell lymphoma that has returned or not responded to prior treatment. The drugs work by helping the immune system recognize and attack cancer cells. The goal is to find …
Matched conditions: REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 26, 2026 09:00 UTC
-
Promising lymphoma combo trial pulled before it began
Disease control TerminatedThis study was designed to test whether combining three drugs—rituximab, venetoclax, and bortezomib—could shrink tumors in people with a fast-growing blood cancer called diffuse large B-cell lymphoma that had come back or stopped responding to standard therapy. The trial was with…
Matched conditions: REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated May 26, 2026 08:57 UTC
-
New combo therapy aims to boost immune attack on tough lymphomas
Disease control OngoingThis phase 2 trial tests whether adding varlilumab to nivolumab helps people with aggressive B-cell lymphomas that have returned or not responded to standard therapy. About 54 participants will receive either nivolumab alone or nivolumab plus varlilumab. The goal is to see if the…
Matched conditions: REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:40 UTC